Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Sai Life Sciences IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1999 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 522  to  549 per share
Profile
Min Investment ₹549
Profile
Lot Size 1
Profile
Face Value ₹1
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Sai Life Sciences Limited, founded in January 1999, specializes in the research, development, and manufacturing of small-molecule new chemical entities. The company provides customized services to biotechnology firms and global pharmaceutical companies. In the financial year 2024, and specifically for the month ending September 30, 2024, Sai Life Sciences served over 280 pharmaceutical innovators, including 18 of the top 25 global pharmaceutical companies by revenue in 2023. These services were extended across key markets, including the US, UK, Europe, and Japan. The company’s business development team consists of 16 qualified professionals based in the US, UK, Europe, and Japan. Sai Life Sciences offers capabilities in chemistry, manufacturing, and control (CMC) through its contract development and manufacturing organization (CDMO) services, alongside contract research organization (CRO) services that integrate discovery capabilities in biology, chemistry, and drug metabolism. As of September 30, 2024, the company employed 3,135 people, with 2,353 scientific staff, including 302 Ph.D. holders and 1,475 master's degree holders. The company’s competitive strength lies in its integrated CRDMO platform, offering comprehensive services from discovery to development and manufacturing, as well as a diverse portfolio of commercial and under-development molecules. Read More

Basic Info

Face Value 1 per share

Price 522  to  549 per share

P/E (x) 62.4

Sales( Cr.) 1695

PAT( Cr.) 170

EPS 8.8

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Shankarlal Deepchand Mehta Kanumuri Ranga Raju Babulal D Mehta Krishnam Raju Kanumuri Jayesh Natvarlal Pithva Kanumuri Mytrey Yashkumar Shankarlal Mehta Sai Quest Syn Private Limited

Pre Issue Share Holding 78.21%

Post Issue Share Holding 57.03%

Listing Details:

Listing Price: 660

Listing Gain: 16.82%

Current Price: 1160

Gain On Issue: 1160 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Dec 11, 2024
Closing Date Dec 13, 2024
Allotment Dec 16, 2024
Refund Dec 17, 2024
Delivery of Shares Dec 17, 2024
Listing Date Dec 18, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 27 14,823
Retail (Max) 13 351 192,699
S-HNI (Min) 14 378 207,522
S-HNI (Max) 67 1809 993,141
B-HNI (Min) 68 1836 1,007,964

Objective of the Issue

1. Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company. 2. General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 2090000 5239630 2.5x
NII 5643000 14640340 2.6x
Retail 13167000 3539580 0.3x
EMP 0 0 0x
Total 20900000 23419550 1.1x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Sai Life Sciences Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 340 425 445 526 695 726 760 870 1217 1465 1695
Other Income 1 4 19 9 6 18 27 28 28 29 37
Total Income 341 429 464 535 701 743 787 898 1245 1494 1731
Total Expenditure 276 345 367 428 520 558 593 745 1048 1178 1287
Operating Profit 65 83 97 108 181 185 195 153 197 316 445
Interest 15 13 12 17 24 22 33 53 81 88 78
Depreciation 19 20 21 27 44 55 80 90 99 119 139
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 31 50 64 63 113 109 82 10 16 109 228
Provision for Tax 7 15 16 21 40 33 21 3 6 26 58
Profit After Tax 24 35 48 42 73 76 61 6 10 83 170
Adjustments 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 24 35 48 42 73 76 61 6 10 83 170
Adjusted Earnings Per Share 1.8 2.5 3.4 3 4.5 4.7 3.5 0.4 0.2 4.7 8.2

Sai Life Sciences Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 220 274 321 367 720 794 863 879 888 975 2128
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 51 39 70 68 77 60 246 297 261 277 0
Other Non-Current Liabilities 26 37 19 35 83 90 109 268 271 316 322
Total Current Liabilities 171 245 238 299 336 467 599 715 759 740 759
Total Liabilities 468 596 648 769 1215 1410 1817 2159 2179 2309 3209
Fixed Assets 213 203 272 307 373 641 753 972 1037 1180 1488
Other Non-Current Assets 47 60 30 43 151 157 260 241 178 184 190
Total Current Assets 208 333 346 420 691 613 804 945 964 945 1531
Total Assets 468 596 648 769 1215 1410 1817 2159 2179 2309 3209

Sai Life Sciences Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 6 1 16 10 -47 192 41 41 116 36 12
Cash Flow from Operating Activities 31 30 19 49 129 116 -36 105 219 263 314
Cash Flow from Investing Activities -18 -30 -69 -62 -158 -262 -260 -104 -102 -192 -537
Cash Flow from Financing Activities -18 15 44 12 268 -4 295 72 -201 -95 301
Net Cash Inflow / Outflow -5 15 -6 -1 239 -150 -1 73 -83 -25 79
Closing Cash & Cash Equivalent 1 16 10 9 192 41 41 116 36 12 91

Sai Life Sciences Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 1.77 2.5 3.41 2.97 4.49 4.66 3.51 0.35 0.18 4.69 8.16
CEPS(Rs) 3.24 3.95 4.89 4.9 7.19 8 8.07 5.49 6.21 11.45 14.81
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 16.54 19.62 22.81 25.57 43.78 48.09 49.08 49.52 49.83 54.59 101.88
Core EBITDA Margin(%) 18.86 18.8 17.48 18.75 25.25 23.11 22.02 14.36 13.88 19.57 24.04
EBIT Margin(%) 13.37 14.86 17.17 15.24 19.69 18.03 15.14 7.23 8 13.41 18.04
Pre Tax Margin(%) 9.03 11.7 14.37 11.93 16.27 15.04 10.78 1.11 1.35 7.44 13.42
PAT Margin (%) 6.92 8.23 10.7 7.99 10.57 10.52 8.04 0.72 0.82 5.64 10.03
Cash Profit Margin (%) 12.65 12.99 15.39 13.2 16.94 18.06 18.51 11.08 8.99 13.78 18.2
ROA(%) 5.12 6.58 7.65 5.93 7.41 5.81 3.79 0.31 0.46 3.69 6.17
ROE(%) 11.34 14.16 16.05 12.34 13.62 10.15 7.44 0.72 1.14 8.99 11.02
ROCE(%) 12.77 15.89 15.93 14.17 17.42 12.65 8.86 4.02 6.06 12.03 15.53
Receivable days 133.26 129.03 167.52 170.36 130.03 126.58 114.17 94.14 79.01 67.19 65.73
Inventory Days 36.29 32.04 33.2 40.64 30.79 22.25 28.91 42.65 39.95 28.23 22.19
Payable days 203.72 168.23 175.93 195.8 195.85 225.9 234.44 230.68 176.27 142.25 180.62
PER(x) 0 0 0 0 0 0 0 0 0 0 93.36
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 7.48
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.46 0.35 0.47 0.44 0.02 0.31 0.76 0.73 0.52 0.39 9.18
EV/Core EBITDA(x) 2.42 1.79 2.14 2.16 0.09 1.2 2.97 4.18 3.2 1.8 34.97
Net Sales Growth(%) 2.46 24.98 4.61 18.34 32.08 4.37 4.74 14.44 39.97 20.38 15.66
EBIT Growth(%) 4.42 38.91 20.87 5.02 70.67 -4.46 -12.03 -45.35 54.96 101.98 55.52
PAT Growth(%) -0.66 48.48 36.12 -11.68 74.8 3.86 -19.95 -89.81 60.44 729 105.45
EPS Growth(%) -1.22 40.99 36.12 -12.9 51.4 3.76 -24.75 -89.88 -50.56 2574.44 74.12
Debt/Equity(x) 0.67 0.57 0.65 0.65 0.35 0.39 0.74 0.86 0.8 0.74 0.06
Current Ratio(x) 1.21 1.36 1.45 1.4 2.06 1.31 1.34 1.32 1.27 1.28 2.02
Quick Ratio(x) 0.99 1.21 1.27 1.16 1.92 1.22 1.21 1.15 1.09 1.16 1.86
Interest Cover(x) 3.08 4.7 6.14 4.6 5.75 6.03 3.47 1.18 1.2 2.25 3.91
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0.01

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 16% 25% 18% 17%
Operating Profit CAGR 41% 43% 19% 21%
PAT CAGR 105% 205% 17% 22%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 62% NA% NA% NA%
ROE Average 11% 7% 6% 10%
ROCE Average 16% 11% 9% 12%

Company Contact Information

Sai Life Sciences Ltd.

Plot No. D S-7, I K P Knowledge Park Turkapally Village, Shameerpet Mandal Medchal- Malkajgiri District

IPO Lead Manager(s)

Sai Life Sciences Ltd.

IIFL Securities Ltd.

Jefferies India Pvt Ltd.

Kotak Mahindra Capital Co Ltd

Morgan Stanley India Co Pvt Ltd

Registrar Info

Sai Life Sciences Ltd.

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District, Nanakramguda Hyderabad – 500032 Tel. No. 040 67161500 Fax. No. 040 23001153 E-mail: einward.ris@karvy.com Website: www.karvy.com Toll Free No. of exclusive Call Centre:1-800-345001

040 - 67162222/18003094001

einward.ris@kfintech.com

https://www.kfintech.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!